BioCentury
ARTICLE | Clinical News

RCN-01303: Began Phase I trial

April 9, 2001 7:00 AM UTC

Receptron Inc., Mountain View, Calif. Product: RCN-01303 Business: Cancer Therapeutic category: Receptor agonist Target: Thrombopoietin (TPO) receptors Description: Peptide TPO activity enhancer Indic...